Loading
A phase 1/2 trial of GV20-0251 in endometrial cancer, head and neck squamous cell carcinoma, non-small-cell lung cancer, melanoma, hepatocellular carcinoma and small-cell lung cancer, run by GV20 Therapeutics, now recruiting.
Study of GV20-0251 in Participants With Solid Tumor Malignancies is a phase 1/2 interventional study registered as NCT07070518 by GV20 Therapeutics, with 350 participants planned, started 2025-07-11 and due to reach its primary completion in 2027-07-16. Interventions recorded: GV20-0251.
Shares GV20 Therapeutics, Endometrial cancer, Head and neck squamous cell carcinoma, Melanoma and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Melanoma, Non-small-cell lung cancer and the tag pipeline.
Shares Endometrial cancer, Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Endometrial cancer, Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Endometrial cancer, Melanoma and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.